risperidone / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 5 Diseases   67 Trials   67 Trials   4266 News 


«12...5152535455565758596061...6364»
  • ||||||||||  risperidone / Generic mfg., Egis
    Ultra-Low Dose of Risperidone Given in Adolescence Prevents Structural Brain and Behavioral Abnormalities Induced by Gestational or Lactational Exposure to Maternal Immune Activation (Regency S-V) -  Apr 3, 2019 - Abstract #SIRS2019SIRS_138;    
    Notably, the behavioral phenotypes are considered to model positive symptoms (disrupted LI and hyper-response to amphetamine, in females prenatally exposed to poly-I:C), negative/cognitive symptoms (persistent LI and hypo-response to amphetamine, in males lactationally exposed to poly-I:C), and depressive symptoms (increased immobility in FST in females lactationally exposed to poly-I:C). We conclude that the neurodevelopmentally compromised brain is remarkably plastic until “symptom” emergence, and that intervention during this pre-symptomatic vulnerability window is trans-risk factors and trans-diagnostic.
  • ||||||||||  risperidone / Generic mfg., Egis, fluoxetine / Generic mfg.
    Two Cases of Brief Affective Psychosis Induced by Diet Aids (Regency S-V) -  Apr 3, 2019 - Abstract #SIRS2019SIRS_89;    
    Her symptoms disappreared in 3 days with risperidone 2mg/day after admission...He has prescribed diet medicines at the local diet clinic with Phentermine, fluoxetine, topiramate and caffeine for about 3 years...Detailed informations and cautions regarding the side effects of diet medicines must be established for customers to know about safety, efficacy and effects of diet therapy. 2
  • ||||||||||  risperidone / Generic mfg., Egis, olanzapine / Generic mfg., quetiapine / Generic mfg.
    Immunomodulatory Effects of Antipsychotic Treatment on Gene Expression in First-Episode Psychosis (Regency S-V) -  Apr 3, 2019 - Abstract #SIRS2019SIRS_37;    
    Our results further emphasize the importance of understanding the immunomodulatory mechanisms of antipsychotic treatment, especially in terms of specific compounds, doses and duration of medication in patients with severe mental illness. Future studies should evaluate the response pre- and post-treatment, and the possible role of this inflammatory activation for the progression of psychiatric and metabolic symptoms.
  • ||||||||||  risperidone / generics, olanzapine / generics, clozapine / generics
    Review, Journal:  Decreased 5-HT2cR and GHSR1a interaction in antipsychotic drug-induced obesity. (Pubmed Central) -  Mar 29, 2019   
    5-HT2cR antagonism by SGAs may disrupt the normal inhibitory tone on the GHSR1a, increasing orexigenic signalling. The 5-HT2cR and its interaction with the GHSR1a could serve as the basis for discovering novel approaches to preventing and treating SGA-induced obesity.
  • ||||||||||  risperidone / generics, donepezil / generics
    Preclinical, Journal:  Stabilized Low-n Amyloid-β Oligomers Induce Robust Novel Object Recognition Deficits Associated with Inflammatory, Synaptic, and GABAergic Dysfunction in the Rat. (Pubmed Central) -  Mar 27, 2019   
    In summary, this study suggested that patients with schizophrenia treated with LAI risperidone had shorter lengths of stay, higher medical costs largely because of increased utilization of outpatient service and hospital admissions, compared with those who took risperidone orally. Taken together the results suggest that acute administration of soluble low-n Aβo may be a useful model to study the early mechanisms involved in AD and provide us with a platform for testing novel therapeutic approaches that target the early underlying synaptic pathology.
  • ||||||||||  risperidone / generics, olanzapine / generics
    Journal:  Pharmacological interventions in social cognition deficits: A systematic mapping review. (Pubmed Central) -  Mar 27, 2019   
    In the different social cognition domains, the majority of publications were focused on emotional processing or theory of mind, with few studies in other domains. Thus, this systematic mapping review shows that, even though there are increasing research activities, there are some important gaps to cover in future investigation.
  • ||||||||||  Edronax (reboxetine) / Pfizer
    Clinical, Journal:  Pharmacological Therapy in Panic Disorder: Current Guidelines and Novel Drugs Discovery for Treatment-resistant Patient. (Pubmed Central) -  Mar 26, 2019   
    Apart for their effectiveness, the aforementioned compounds were generally well tolerated compared to the standard available pharmacotherapy drugs, indicating their potential therapeutic usefulness for ambivalent and hypervigilance patient. Further strong clinical trials will provide an ample support to these novel compounds as an alternative monotherapy for PD treatment-resistant patient.
  • ||||||||||  Abilify Maintena (aripiprazole depot formulation) / Otsuka, BMS, Lundbeck, Saphris (asenapine) / Allergan, Lundbeck, Meiji Seika
    Journal:  Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines. (Pubmed Central) -  Mar 26, 2019   
    ...Quetiapine, olanzapine and aripiprazole were the first-line AAPs for nearly all phases of bipolar disorder across guidelines...As research evidence accumulated over time, recommendations of newer AAPs (such as asenapine, cariprazine, paliperidone, lurasidine, long-acting injectable risperidone and aripiprazole once monthly) became prominent...Strong preference for combination therapy was characteristic of KMAP-BP 2018, predominantly in the treatment of psychotic mania and severe depression. Further studies were needed to address several issues identified in our review.
  • ||||||||||  risperidone / Generic mfg.
    New P2 trial:  Therapeutic Issues for Autism (clinicaltrials.gov) -  Mar 25, 2019   
    P2,  N=80, Completed, 
  • ||||||||||  Moban (molindone) / Impax, Latuda (lurasidone oral) / Sumitomo Dainippon, Geodon (ziprasidone) / RaQualia, Meiji Seika, Pfizer
    Retrospective data, Review, Journal:  Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis. (Pubmed Central) -  Mar 25, 2019   
    The highest weight gain was found for clozapine, quetiapine and olanzapine...Risperidone, haloperidol, paliperidone and olanzapine were associated with prolactin increase...Most of the comparisons are based only on one study or just on indirect evidence. Nevertheless, the available direct and indirect evidence showed that the treatment effects were similar compared to findings in adult patients with schizophrenia.
  • ||||||||||  Geodon (ziprasidone) / RaQualia, Meiji Seika, Pfizer
    Review, Journal:  Antipsychotic Use During Pregnancy and the Risk of Gestational Diabetes Mellitus: A Systematic Review. (Pubmed Central) -  Mar 25, 2019   
    Findings from some studies suggesting a higher risk of GDM in pregnant women who were administered antipsychotic drugs were not confirmed by results of many other studies. The current evidence suggests no significant relationship between antipsychotic drugs, including second- and first-generation antipsychotics, and the risk of GDM.
  • ||||||||||  Trial completion date, Trial primary completion date:  The Optimal Treatment for Treatment-resistant Schizophrenia (clinicaltrials.gov) -  Mar 13, 2019   
    P=N/A,  N=150, Recruiting, 
    The publications on SGAs in Malaysia have undergone exponential growth, without evidence a saturation point. Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: Sep 2018 --> Sep 2019
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Cross-Sectional Iloperidone IVGTT (clinicaltrials.gov) -  Mar 12, 2019   
    P=N/A,  N=37, Completed, 
    Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: Sep 2018 --> Sep 2019 Recruiting --> Completed | N=60 --> 37 | Trial completion date: Dec 2015 --> May 2016 | Trial primary completion date: Dec 2015 --> May 2016
  • ||||||||||  risperidone / Generic mfg., olanzapine / Generic mfg., quetiapine / Generic mfg.
    Trial completion date, Trial primary completion date:  Deprescribing Antipsychotics in Long-Term Care (clinicaltrials.gov) -  Mar 8, 2019   
    P=N/A,  N=20, Recruiting, 
    Recruiting --> Completed | N=60 --> 37 | Trial completion date: Dec 2015 --> May 2016 | Trial primary completion date: Dec 2015 --> May 2016 Trial completion date: Dec 2018 --> Aug 2019 | Trial primary completion date: Oct 2018 --> Jan 2019
  • ||||||||||  Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
    Trial completion, Enrollment change:  Study of the Impact of Aripiprazole (Abilify (clinicaltrials.gov) -  Feb 18, 2019   
    P4,  N=47, Completed, 
    Trial completion date: Jan 2019 --> Jan 2020 Recruiting --> Completed | N=80 --> 47
  • ||||||||||  risperidone / Generic mfg., oxycodone controlled release / Generic mfg., ziprasidone / Generic mfg.
    New P1 trial:  Reducing the Abuse of Opioids in Drug Users (clinicaltrials.gov) -  Feb 11, 2019   
    P1,  N=25, Not yet recruiting, 
  • ||||||||||  Lu AF35700 / Lundbeck, Jiangsu NHWA Pharma
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia (clinicaltrials.gov) -  Feb 11, 2019   
    P3,  N=120, Terminated, 
    Trial completion date: Aug 2019 --> Apr 2020 | Trial primary completion date: Aug 2019 --> Apr 2020 N=817 --> 120 | Trial completion date: Sep 2020 --> Feb 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2020 --> Feb 2019; New data; the study was terminated based on new efficacy data from another study
  • ||||||||||  Lu AF35700 / Lundbeck, Jiangsu NHWA Pharma
    Enrollment closed:  Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia (clinicaltrials.gov) -  Jan 28, 2019   
    P3,  N=817, Active, not recruiting, 
    N=817 --> 120 | Trial completion date: Sep 2020 --> Feb 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2020 --> Feb 2019; New data; the study was terminated based on new efficacy data from another study Recruiting --> Active, not recruiting
  • ||||||||||  Enrollment closed, Trial completion date, Trial primary completion date:  Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia (clinicaltrials.gov) -  Jan 17, 2019   
    P=N/A,  N=14, Active, not recruiting, 
    Recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020
  • ||||||||||  aripiprazole / Generic mfg., risperidone / Generic mfg.
    Enrollment open:  LAP01: Long-term Antipsychotic Pediatric Safety Trial (clinicaltrials.gov) -  Jan 10, 2019   
    P=N/A,  N=700, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020 Not yet recruiting --> Recruiting
  • ||||||||||  aripiprazole / Generic mfg., risperidone / Generic mfg.
    P4 data, Trial initiation date:  LAP01: Long-term Antipsychotic Pediatric Safety Trial (clinicaltrials.gov) -  Dec 14, 2018   
    P=N/A,  N=700, Not yet recruiting, 
    Not yet recruiting --> Recruiting Initiation date: Oct 2018 --> Jan 2019
  • ||||||||||  risperidone controlled-release implant (BB-0817) / Braeburn
    Trial termination:  Safety and Tolerability of Risperidone Implants (clinicaltrials.gov) -  Dec 6, 2018   
    P3,  N=140, Terminated, 
    N=50 --> 66 | Active, not recruiting --> Terminated Active, not recruiting --> Terminated
  • ||||||||||  aripiprazole / Generic mfg., risperidone / Generic mfg.
    P4 data, Trial initiation date:  LAP01: Long-term Antipsychotic Pediatric Safety Trial (clinicaltrials.gov) -  Oct 22, 2018   
    P=N/A,  N=700, Not yet recruiting, 
    Trial completion date: Oct 2018 --> Aug 2019 | Trial primary completion date: Oct 2018 --> Aug 2019 Initiation date: Jul 2018 --> Oct 2018